0.3838

5.47% 0.0199

After Hours: .37 -0.0138 -3.60%

Mersana Therapeutics Inc (MRSN)

Overview News Price History Option Chain Financials Discussions Forecast

Mersana Therapeutics Inc stock is traded at $0.3838, with a volume of 2.06M. It is up +5.47% in the last 24 hours and up +1.13% over the past month. Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.

Previous Close:

$0.3639

Open:

$0.3625

24h Volume:

2.06M

Relative Volume:

0.55

Market Cap:

$40.74M

Revenue:

$36.86M

Net Income/Loss:

$-171.67M

P/E Ratio:

-0.2559

EPS:

-1.5

Net Cash Flow:

$-171.05M

1W Performance:

+17.41%

1M Performance:

+1.13%

6M Performance:

-81.19%

1Y Performance:

-86.95%

1-Day Range:

$0.355

$0.3929

1-Week Range:

$0.3301

$0.4298

52-Week Range:

$0.2589

$3.63

Mersana Therapeutics Inc Stock (MRSN) Company Profile

Name

Mersana Therapeutics Inc

Sector

Healthcare (1153)

Industry

Biotechnology (673)

Phone

617-498-0020

Address

840 MEMORIAL DRIVE, CAMBRIDGE

Employee

102

Twitter

@MersanaADC

Next Earnings Date

2025-03-03

Latest SEC Filings

MRSN's Discussions on Twitter

Compare MRSN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MRSN Mersana Therapeutics Inc	0.3838	40.74M	36.86M	-171.67M	-171.05M	-1.50
VRTX Vertex Pharmaceuticals Inc	496.49	122.76B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	610.86	61.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	620.97	36.37B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	254.85	30.12B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.46	24.70B	3.81B	-644.79M	-669.77M	-6.24

Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-06-25	Initiated	William Blair	Outperform
Nov-15-24	Resumed	Citigroup	Buy
Mar-19-24	Upgrade	JP Morgan	Underweight → Neutral
Feb-29-24	Upgrade	BTIG Research	Neutral → Buy
Feb-29-24	Upgrade	Guggenheim	Neutral → Buy
Feb-29-24	Upgrade	Wedbush	Neutral → Outperform
Dec-04-23	Upgrade	Citigroup	Neutral → Buy
Jul-28-23	Downgrade	Robert W. Baird	Outperform → Neutral
Jul-27-23	Downgrade	BTIG Research	Buy → Neutral
Jul-27-23	Downgrade	Citigroup	Buy → Neutral
Jul-27-23	Downgrade	Guggenheim	Buy → Neutral
Jul-27-23	Downgrade	JP Morgan	Neutral → Underweight
Jul-27-23	Downgrade	Truist	Buy → Hold
Jul-27-23	Downgrade	Wedbush	Outperform → Neutral
Jun-16-23	Downgrade	JP Morgan	Overweight → Neutral
Jun-15-23	Initiated	Guggenheim	Buy
Mar-16-23	Upgrade	JP Morgan	Neutral → Overweight
Jan-20-23	Initiated	Citigroup	Buy
Nov-21-22	Initiated	Truist	Buy
Oct-15-21	Resumed	BTIG Research	Buy
Aug-30-21	Initiated	H.C. Wainwright	Buy
Mar-31-21	Initiated	Credit Suisse	Neutral
Dec-03-20	Initiated	Stifel	Buy
Sep-29-20	Resumed	JP Morgan	Neutral
Apr-29-20	Initiated	BTIG Research	Buy
Jan-21-20	Reiterated	H.C. Wainwright	Buy
Mar-11-19	Downgrade	JP Morgan	Neutral → Underweight
Nov-14-18	Upgrade	Leerink Partners	Mkt Perform → Outperform
May-08-18	Initiated	Robert W. Baird	Outperform
Mar-19-18	Downgrade	JP Morgan	Overweight → Neutral

View All

Mersana Therapeutics Inc Stock (MRSN) Latest News

Apr 28, 2025

Investors’ Faith in Mersana Therapeutics Inc (MRSN) could reap rewards if they hold on for the long haul - uspostnews.com

Apr 28, 2025

Investor’s Delight: Mersana Therapeutics Inc (MRSN) Closes Strong at 0.36, Up 0.44 - DWinneX

Apr 28, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Stock Holdings Lifted by Geode Capital Management LLC - Defense World

Apr 28, 2025

Apr 25, 2025

MRSN Shares Experience Decline in Value - knoxdaily.com

Apr 25, 2025

Mersana therapeutics VP Mandelia sells $1,128 in stock - MSN

Apr 25, 2025

Apr 23, 2025

Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting | MRSN Stock News - GuruFocus

Apr 23, 2025

Mersana Therapeutics Announces Presentations on Emiltatug Ledadotin at ASCO 2025 Annual Meeting - Nasdaq

Apr 23, 2025

Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting - GlobeNewswire

Apr 23, 2025

Breakthrough Cancer Drug Emi-Le Earns Dual FDA Fast Track Status: Key Data Coming at ASCO 2025 - Stock Titan

Apr 23, 2025

Daily Market Movement: Mersana Therapeutics Inc (MRSN) Sees a 15.02 Increase, Closing at 0.38 - DWinneX

Apr 23, 2025

Mersana Therapeutics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - investchronicle.com

Apr 23, 2025

It makes sense and dollars to buy Mersana Therapeutics Inc (MRSN) stock - Sete News

Apr 23, 2025

Apr 22, 2025